Fractyl Health is a pioneering biotech company based in Waltham, MA, dedicated to developing transformative therapies for metabolic diseases such as type 2 diabetes (T2D) and obesity. Their mission-driven team of innovators focuses on targeting the root causes of these conditions and delivering therapies to patients as quickly and widely as possible.
Fractyl Health's breakthrough therapies include Revita, an outpatient procedural therapy designed to modify duodenal dysfunction and restore metabolic health, and Rejuva, a novel gene therapy platform in preclinical development that aims to improve islet function and potentially enable long-term remission of T2D and obesity. With a vision to prevent and eliminate metabolic diseases, Fractyl Health is at the forefront of developing innovative solutions for these global health challenges.
Generated from the website